JP2011519574A - 細胞ベースの治療に関連する材料および方法 - Google Patents

細胞ベースの治療に関連する材料および方法 Download PDF

Info

Publication number
JP2011519574A
JP2011519574A JP2011507987A JP2011507987A JP2011519574A JP 2011519574 A JP2011519574 A JP 2011519574A JP 2011507987 A JP2011507987 A JP 2011507987A JP 2011507987 A JP2011507987 A JP 2011507987A JP 2011519574 A JP2011519574 A JP 2011519574A
Authority
JP
Japan
Prior art keywords
cells
cell population
positive
tissue
adult
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011507987A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011519574A5 (cg-RX-API-DMAC7.html
Inventor
ポール シールズ,
Original Assignee
ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ グラスゴー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ グラスゴー filed Critical ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ グラスゴー
Publication of JP2011519574A publication Critical patent/JP2011519574A/ja
Publication of JP2011519574A5 publication Critical patent/JP2011519574A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
JP2011507987A 2008-05-09 2009-05-08 細胞ベースの治療に関連する材料および方法 Pending JP2011519574A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5209808P 2008-05-09 2008-05-09
US61/052,098 2008-05-09
PCT/GB2009/001149 WO2009136168A1 (en) 2008-05-09 2009-05-08 Materials and methods relating to cell based therapies

Publications (2)

Publication Number Publication Date
JP2011519574A true JP2011519574A (ja) 2011-07-14
JP2011519574A5 JP2011519574A5 (cg-RX-API-DMAC7.html) 2012-06-21

Family

ID=40935531

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011507987A Pending JP2011519574A (ja) 2008-05-09 2009-05-08 細胞ベースの治療に関連する材料および方法

Country Status (5)

Country Link
US (2) US20110158961A1 (cg-RX-API-DMAC7.html)
EP (1) EP2283115A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011519574A (cg-RX-API-DMAC7.html)
CN (1) CN102083964B (cg-RX-API-DMAC7.html)
WO (1) WO2009136168A1 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015522281A (ja) * 2012-06-26 2015-08-06 セラクシス,インコーポレーテッド インスリン依存性糖尿病の治療に有用な幹細胞と膵臓細胞
WO2018034023A1 (ja) * 2016-08-18 2018-02-22 北海道公立大学法人札幌医科大学 寿命延長剤
JP2022501045A (ja) * 2018-09-21 2022-01-06 アプステム セラピューティクス、インコーポレイテッド ヒト多能性成人幹細胞
US12203096B2 (en) 2017-04-04 2025-01-21 The Board Of Trustees Of The Leland Stanford Junior University Preparation, expansion, and uses of adult pluripotent stem cells

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2603592A2 (en) 2010-08-13 2013-06-19 The University Court of the University of Glasgow Therapeutic uses of microvesicles and related micrornas
WO2014091373A1 (en) 2012-12-11 2014-06-19 The University Court Of The University Of Glasgow Cellular and molecular therapies for peripheral vascular disease
CA3019514A1 (en) * 2016-03-30 2017-10-05 Asterias Biotherapeutics, Inc. Oligodendrocyte progenitor cell compositions
US20190085296A1 (en) * 2017-09-20 2019-03-21 Sergio Mora Method of expansion of human pancreas progenitor cells from stem cells using feeder-conditioned media
AU2019342741B2 (en) 2018-09-19 2025-12-11 Lineage Cell Therapeutics, Inc. Methods for differentiating pluripotent stem cells in dynamic suspension culture
AU2020210757B2 (en) 2019-01-23 2026-04-16 Asterias Biotherapeutics, Inc. Dorsally-derived oligodendrocyte progenitor cells from human pluripotent stem cells
CN113710285A (zh) * 2019-03-26 2021-11-26 宾州研究基金会 用于治疗癌症的方法和材料
MX2023003655A (es) 2020-09-29 2023-06-22 Neuexcell Therapeutics Inc Vector neurod1.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006120476A1 (en) * 2005-05-13 2006-11-16 The University Court Of The University Of Glasgow Materials and methods relating to cell based therapies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020012653A1 (en) * 1997-12-19 2002-01-31 Kevin Pang Bile duct progenitor cells and methods of use
US6878543B1 (en) * 1999-10-25 2005-04-12 Nsgene Sa Cultures of GFAP+ nestin+ cells that differentiate to neurons
EP2287290B1 (en) * 2001-09-20 2016-05-11 AntiCancer, Inc. Nestin-expressing hair follicle stem cells
US20040029269A1 (en) * 2002-05-07 2004-02-12 Goldman Steven A Promoter-based isolation, purification, expansion, and transplantation of neuronal progenitor cells, oligodendrocyte progenitor cells, or neural stem cells from a population of embryonic stem cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006120476A1 (en) * 2005-05-13 2006-11-16 The University Court Of The University Of Glasgow Materials and methods relating to cell based therapies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6013057430; STEVENSON,K.S. et al.: 'Isolation, characterization, and differentiation of thy1.1-sorted pancreatic adult progenitor cell p' Stem Cells Dev. Vol.18, No.10, 200912, pp.1389-98 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015522281A (ja) * 2012-06-26 2015-08-06 セラクシス,インコーポレーテッド インスリン依存性糖尿病の治療に有用な幹細胞と膵臓細胞
JP2018193394A (ja) * 2012-06-26 2018-12-06 セラクシス,インコーポレーテッド インスリン依存性糖尿病の治療に有用な幹細胞と膵臓細胞
WO2018034023A1 (ja) * 2016-08-18 2018-02-22 北海道公立大学法人札幌医科大学 寿命延長剤
JPWO2018034023A1 (ja) * 2016-08-18 2019-06-13 北海道公立大学法人 札幌医科大学 寿命延長剤
US12203096B2 (en) 2017-04-04 2025-01-21 The Board Of Trustees Of The Leland Stanford Junior University Preparation, expansion, and uses of adult pluripotent stem cells
JP2022501045A (ja) * 2018-09-21 2022-01-06 アプステム セラピューティクス、インコーポレイテッド ヒト多能性成人幹細胞
JP7329265B2 (ja) 2018-09-21 2023-08-18 アプステム セラピューティクス、インコーポレイテッド ヒト多能性成人幹細胞
US11845956B2 (en) 2018-09-21 2023-12-19 APstem Therapeutics, Inc. Human pluripotent adult stem cells
US12644098B2 (en) 2018-09-21 2026-06-02 APstem Therapeutics, Inc. Human pluripotent adult stem cells

Also Published As

Publication number Publication date
WO2009136168A1 (en) 2009-11-12
US20130280219A1 (en) 2013-10-24
EP2283115A1 (en) 2011-02-16
CN102083964A (zh) 2011-06-01
US20110158961A1 (en) 2011-06-30
CN102083964B (zh) 2013-06-12
HK1157814A1 (en) 2012-07-06

Similar Documents

Publication Publication Date Title
JP2011519574A5 (cg-RX-API-DMAC7.html)
CN102083964B (zh) 与基于细胞的疗法相关的材料和方法
Passier et al. Origin and use of embryonic and adult stem cells in differentiation and tissue repair
JP4146802B2 (ja) 単球を起源に持つ、脱分化したプログラム可能な幹細胞およびそれらの製造と使用
Dabeva et al. Hepatic stem cells and liver repopulation
CA2867953C (en) Regulating stem cells
CN112891374B (zh) 治疗中风的影响的方法
JP2014000096A (ja) ヒト胚性幹細胞の造血分化
JPWO2008153179A1 (ja) 脂肪組織由来多系統前駆細胞
JP6860921B2 (ja) 血液細胞を用いた組織・臓器の作製方法
WO2012133948A1 (ja) 生体組織から単離できるssea-3陽性の多能性幹細胞を含む他家移植用細胞治療用組成物
EP1896571B1 (en) Materials and methods relating to cell based therapies
Kao et al. Comparisons of differentiation potential in human mesenchymal stem cells from Wharton’s jelly, bone marrow, and pancreatic tissues
CN113573720A (zh) 提高视力的方法
JPWO2004101775A1 (ja) 新規な成体組織由来の幹細胞およびその用途
WO2004083414A1 (ja) 単球由来多能性細胞momc
Moshrefi et al. Transplantation of differentiated umbilical cord mesenchymal cells under kidney capsule for control of type I diabetes in rat
Watanabe et al. Differentiation of a hepatic phenotype after heterotropic transplantation of heart, kidney, brain, and skin tissues into liver in F344 rats
Rios et al. Stem cells and their contribution to tissue repair
HK1157814B (en) Materials and methods relating to cell based therapies
Yeung Mesenchymal Stem Cells In Islet Transplantion
Piscaglia et al. 2 Oval Cells, Bone Marrow, and Liver
Wong Bone Marrow Stem Cell-mediated Airway Epithelial Regeneration
Blastocysts Perspectives: Plasticity of Stem Cells
IL193947A (en) Cells cultured as cd31brigi: it, a method for stimuli to differentiate into a congenital / precursor cell population (pcp), use of the same drug preparation population, and implantation device that includes it

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140218

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140318

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140326

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140418

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140520

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141003